Treatment of prostate cancer with AR inhibition may lead to selection for cancer cells with elevated ONECUT2 expression, thereby contributing to resistance to AR-targeted therapy and development of NE features that lead to more aggressive phenotypes with worse clinical outcomes[2,3,5]. This evidence concerns the gene ONECUT2 and Familial prostate cancer.